当前位置: 首页 >> 检索结果
203. Prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity: a WHO individual participant data meta-analysis.
作者: Ioannis Gallos.;Caitlin R Williams.;Malcolm J Price.;Aurelio Tobias.;Adam Devall.;John Allotey.;Fernando Althabe.;Jenny A Cresswell.;Jill Durocher.;A Metin Gülmezoglu.;Christian Haslinger.;Rodolfo C Pacagnella.;Loïc Sentilhes.;Soha Sobhy.;Idnan Yunas.;Jonathan J Deeks.;Arri Coomarasamy.;Olufemi T Oladapo.; .
来源: Lancet. 2025年406卷10514期1969-1982页
Postpartum haemorrhage (excessive bleeding after birth) is a leading cause of maternal mortality and morbidity worldwide. However, there is no global consensus on which clinical markers best define excessive bleeding or reliably predict adverse maternal outcomes. The aim of this study was to assess the prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity.
204. New Ebola virus disease outbreak in the Democratic Republic of the Congo: early response guidance.
作者: Dieudonne Mwamba.;Franck Mboussou.;Pierre Akilimali.;Christian Ngandu.;Benido Impouma.;Chikwe Ihekwazu.;Samuel Roger Kamba.;Mohamed Yakub Janabi.
来源: Lancet. 2025年406卷10512期1557-1558页 205. Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
作者: David J Lewis.;Mats Jerkeman.;Lexy Sorrell.;David Wright.;Ingrid Glimelius.;Christian B Poulsen.;Annika Pasanen.;Andrew Rawstron.;Karin F Wader.;Nick Morley.;Catherine Burton.;Andrew J Davies.;Ingemar Lagerlöf.;Surita Dalal.;Ruth De Tute.;Chris McNamara.;Nicola Crosbie.;Helle Erbs Toldbod.;Jeanette Sanders.;Victoria Allgar.;Sree Aroori.;Mark Warner.;Claire Scully.;Brian Wainman.;Jacob Haaber Christensen.;Jon Riise.;Kristina Sonnevi.;Mark J Bishton.;Toby A Eyre.;Simon Rule.; .
来源: Lancet. 2025年406卷10514期1953-1968页
Ibrutinib, a Bruton tyrosine kinase inhibitor, prolongs progression-free survival when added to immunochemotherapy as first line treatment. The ENRICH trial compared the chemotherapy-free combination of ibrutinib and the anti-CD20 antibody rituximab (ibrutinib-rituximab) with standard immunochemotherapy (R-CHOP [rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone] or bendamustine-rituximab) in patients 60 years and older with untreated mantle-cell lymphoma.
209. The EAT-Lancet Commission on healthy, sustainable, and just food systems.
作者: Johan Rockström.;Shakuntala Haraksingh Thilsted.;Walter C Willett.;Line J Gordon.;Mario Herrero.;Christina C Hicks.;Daniel Mason-D'Croz.;Nitya Rao.;Marco Springmann.;Ellen Cecilie Wright.;Rina Agustina.;Sumati Bajaj.;Anne Charlotte Bunge.;Bianca Carducci.;Costanza Conti.;Namukolo Covic.;Jessica Fanzo.;Nita G Forouhi.;Matthew F Gibson.;Xiao Gu.;Ermias Kebreab.;Claire Kremen.;Amar Laila.;Ramanan Laxminarayan.;Theresa M Marteau.;Carlos A Monteiro.;Anna Norberg.;Jemimah Njuki.;Thais Diniz Oliveira.;Wen-Harn Pan.;Juan A Rivera.;James P W Robinson.;Marina Sundiang.;Sofie Te Wierik.;Detlef P van Vuuren.;Sonja Vermeulen.;Patrick Webb.;Lujain Alqodmani.;Ramya Ambikapathi.;Anne Barnhill.;Isabel Baudish.;Felicitas Beier.;Damien Beillouin.;Arthur H W Beusen.;Jannes Breier.;Charlotte Chemarin.;Maksym Chepeliev.;Jennifer Clapp.;Wim de Vries.;Ignacio Pérez-Domínguez.;Natalia Estrada-Carmona.;Dieter Gerten.;Christopher D Golden.;Sarah K Jones.;Peter Søgaard Jørgensen.;Marta Kozicka.;Hermann Lotze-Campen.;Federico Maggi.;Emma Marzi.;Abhijeet Mishra.;Fernando Orduna-Cabrera.;Alexander Popp.;Lena Schulte-Uebbing.;Elke Stehfest.;Fiona H M Tang.;Kazuaki Tsuchiya.;Hannah H E Van Zanten.;Willem-Jan van Zeist.;Xin Zhao.;Fabrice DeClerck.
来源: Lancet. 2025年406卷10512期1625-1700页 |